Advertisement

BRIEF-Novartis Says Premenopausal Women Taking Kisqali Benefited For Longer Time Until Health-Related QOL Deterioration

BRIEF-Novartis Says Premenopausal Women Taking Kisqali Benefited For Longer Time Until Health-Related QOL Deterioration
From Reuters - December 6, 2017

Dec 6 (Reuters) - Novartis Ag:

* NOVARTIS KISQALI IS FIRST AND ONLY CDK4/6 INHIBITOR TO SHOW SUPERIOR MEDIAN PFS COMPARED TO ORAL ENDOCRINE THERAPY AS FIRST-LINE TREATMENT IN A PROSPECTIVE, RANDOMIZED PHASE III TRIAL DEDICATED TO PREMENOPAUSAL WOMEN WITH HR+/HER2- ADVANCED BREAST CANCER

* NOVARTIS - PREMENOPAUSAL WOMEN TAKING KISQALI BENEFITED FOR LONGER TIME UNTIL HEALTH-RELATED QOL DETERIORATION VERSUS THOSE TAKING ENDOCRINE THERAPY ALONE

Advertisement

Continue reading at Reuters »